Support for Clinical Development and Evidence Generation

12.1 The MSL’s Role in Investigator-Sponsored Research and Collaborative Studies

Investigator-sponsored research is one of the areas where the MSL can create real value and real risk at the same time. The value is straightforward. MSLs spend time with physicians who are not only users of evidence but also creators of it. They hear where clinicians believe current data are insufficient, which patient populations remain poorly understood, what practical questions arise repeatedly in care, and which external experts have the scientific seriousness to explore those questions in a disciplined way. That field proximity makes the MSL a natural early detector of research ideas worth surfacing.

But the risk is just as real. An MSL is not there to casually generate studies on behalf of the company, promise support, shape research questions to fit commercial hopes, or operate as an unofficial trial manager. The role in investigator-sponsored research is best understood as scientific interface, process guide, and relationship steward. The MSL may recognize an investigator with a credible concept, explain the company’s process for research submissions, help ensure that the scientific rationale is expressed clearly enough for review, and maintain the broader scientific relationship. What the MSL should not do is pre-negotiate outcomes or imply that enthusiasm in the field equals funding approval.

A useful way to think about ISR support is to divide it into stages. In the earliest stage, the MSL often hears an idea in raw form. A physician may say that the current data do not answer an important question in older patients, in a biomarker-defined subgroup, in real-world sequencing, or in combination with another approach. At that point, the MSL’s job is not to “develop the study.” The job is to understand whether the concept reflects a real evidence gap, whether the physician seems scientifically credible, and whether the question appears relevant enough to direct the investigator to the appropriate internal process. The MSL should listen carefully, ask clarifying scientific questions where allowed, and avoid making any suggestion that the company has already judged the concept favorably.

Once an investigator expresses genuine interest, the MSL can often be helpful by explaining process boundaries. Many physicians do not know how company-supported investigator research is reviewed. They may assume that local enthusiasm or existing relationships will determine the outcome. A mature MSL explains that there is a formal submission path, defined review criteria, and separation between field relationship and internal approval. That explanation protects both parties. It helps the investigator understand what is required, and it protects the MSL from sliding into informal promises.

The MSL can also help by recognizing what makes a concept stronger scientifically. Without writing the proposal for the investigator, the MSL may encourage sharper articulation of the clinical question, clearer thinking about the target population, stronger linkage to unmet need, or a more realistic view of feasibility. The distinction matters. Helping a physician express a scientifically sound question more clearly is appropriate. Engineering the proposal to improve its internal odds by aligning it with hidden company preferences is not.

Collaborative studies broaden the picture further. Not every externally generated evidence opportunity is a classic investigator-sponsored trial. Some are registries, retrospective chart reviews, real-world evidence collaborations, biomarker analyses, database studies, survey-based clinical practice assessments, or institution-based quality projects with scientifically relevant implications. Here again, the MSL’s value often lies in recognizing when a field needs points toward a practical evidence opportunity and then routing that opportunity to the right internal team.

In many organizations, the medical  field can be especially valuable in identifying studies that matter because they are close to care delivery realities. Headquarters may naturally focus on questions that look strategically elegant. Clinicians often focus on questions that affect actual treatment behavior: how to identify the right patient sooner, how to manage monitoring burden, how to understand outcomes in less selected populations, or how new therapy use interacts with existing pathways and referral patterns. These are not lesser questions. In many cases, they are exactly the questions that determine whether evidence becomes usable medicine.

That said, the MSL should not become the owner of ISR execution. Once a project moves forward, governance usually shifts to the company’s research, grants, medical affairs, or study management structures. The MSL may remain an important scientific touchpoint in the relationship, but should not be functioning as the person who chases contracts, manages milestones, resolves operational bottlenecks, or informally pressures progress. Scientific relationship support is appropriate. Operational ownership is not.

Several practical guardrails help keep the role clean:

• No promises: do not imply approval, funding, or likely support before formal review.
• No back-channel shaping: do not guide the proposal toward hidden commercial objectives.
• No operational substitution: do not become the study coordinator, monitor, or informal project manager.
• No selective enthusiasm: assess concepts for scientific merit and relevance, not for perceived brand advantage alone.

The best MSLs in this area develop a reputation for being helpful without being compromising. Investigators learn that these MSLs understand the science, respect the process, and do not overstate their influence. Internally, those same MSLs become trusted sources of externally grounded research opportunities because they know which ideas are real, which are speculative, and which investigators are likely to execute with rigor.

One final point is worth emphasizing. A company does not need every field idea to become a study. In fact, most should not. The MSL’s job is not to flood the system with concepts. It is to surface the few ideas and collaborators that meaningfully strengthen the evidence agenda. Selectivity is part of professionalism here. The field medical function adds value when it improves the signal entering research governance, not when it increases noise.

12.2 Supporting Site Relationships and Trial Awareness Appropriately

MSLs often work near the edges of clinical development even when they are not formally part of the trial execution team. They know investigators, understand institutional culture, and hear practical reactions to protocol ideas and scientific questions that shape whether studies are seen as relevant. This proximity creates legitimate opportunities to support site relationships and study awareness. It also creates temptation to drift into operational work that belongs to clinical operations or clinical science. Managing that boundary well is one of the clearest marks of a mature field medical organization.

The first area of contribution is relationship continuity. Many important sites know the company through several functions over time: clinical development during one study, medical affairs during a launch, evidence-generation teams around real-world work, and field medical across the full life cycle. The MSL often provides continuity across those moments. A trusted MSL may understand the institution’s scientific culture, the investigator’s interests, the historical relationship with the company, and the difference between a site that is genuinely research capable and one that is merely prestigious. That context can be very useful internally when thinking about future collaboration.

The second area is appropriate study awareness. In some settings, physicians may be unaware of ongoing clinical trials, future development directions, or the scientific rationale for a study even when that awareness would be valuable to patients and institutions. Within company policy and role boundaries, an MSL may help ensure that appropriate stakeholders know a study exists, understand its basic scientific purpose, and know how to connect with the responsible clinical team for operational details. This is not the same as driving enrollment. The objective is scientific awareness and responsible routing, not target-chasing.

That distinction matters. The MSL should not function like an enrollment accelerator whose success is judged by whether more patients enter a study. The moment the role becomes tied to recruitment pressure, the quality of the scientific relationship changes. Investigators can feel the difference quickly. They may still engage, but the MSL’s credibility as a medical peer begins to erode. A better standard is this: the MSL can help ensure that scientifically appropriate stakeholders understand the trial and can find the right operational pathway if they are interested.

MSLs can also help clarify the scientific relevance of a trial. Physicians often want to know why the study matters, how the population was chosen, what question the design is trying to answer, and where the data may fit in the broader treatment landscape if positive. Those are appropriate scientific conversations. The MSL can add value by explaining the rationale in language that reflects both the disease area and the clinician’s likely concerns. Where the questions become protocol-specific, operational, or regulatory, the MSL should know when to hand off to clinical colleagues.

This is especially important at sites with mixed levels of sophistication. Some investigators want detailed protocol discussion from the beginning. Others first want to know whether the study addresses a real clinical question and whether the eligibility criteria seem relevant to their practice. The MSL should meet them where they are scientifically without taking ownership of work that belongs elsewhere.

Site support also includes awareness of institutional realities. The MSL may know that one center struggles with biomarker turnaround time, another is overloaded operationally despite strong scientific interest, and another has a pathway committee that will scrutinize trial relevance closely before encouraging referrals. That knowledge can help internal teams avoid unrealistic assumptions. But again, the MSL’s role is interpretive and connective, not operational. The MSL is there to help the company understand the site, not to solve every site problem personally.

Several behaviors should remain clearly out of scope. The MSL should not negotiate budgets or contracts, should not collect source data, should not pressure investigators about enrollment numbers, should not act as a substitute for monitoring or study management, and should not improvise answers to protocol questions that require formal clinical ownership. Even when a site prefers dealing with the MSL because the relationship is stronger, role discipline matters. Being useful is good. Becoming the wrong person for the job is not.

A practical field standard is to distinguish three types of support. Scientific support: explaining rationale, understanding investigator questions, and maintaining medical relationships. Routing support: connecting the site to the right clinical team, process, or scientific follow-up. Operational support: execution work owned by clinical operations or study teams. The MSL belongs clearly in the first two and should be cautious not to drift into the third.

In large organizations, the handoff between field medical and clinical teams should be explicit. If an investigator asks a question about study design rationale, that may belong in a medical or clinical science discussion. If the question is about startup timelines, contract status, inclusion logistics, or patient screening workflow, clinical operations should lead. The MSL can facilitate a smooth transition, but should not carry the whole burden because it seems faster at the moment.

One useful internal checklist for site-related engagement is simple:

• Is the discussion scientific: if yes, the MSL may be the right interface.
• Is the discussion operational: if yes, route to the clinical team.
• Is the relationship sensitive: if yes, coordinate carefully so the company appears unified.
• Is there any enrollment pressure: if yes, step back and protect the role boundary.

When done well, MSL support around sites and trials improves institutional trust. Investigators see a company that knows how to separate scientific dialogue from study operations while still coordinating intelligently. Internally, clinical teams benefit from field context without confusing field medical with operational capacity. That is exactly the balance the role should strike.

12.3 Bringing Field Feedback Into Evidence Generation Plans

One of the most strategic contributions an MSL can make is helping the company understand what evidence it still needs. Clinical development plans are often built from internal scientific logic, regulatory requirements, and portfolio priorities. All of that matters. But it is not enough. External clinicians see where the current evidence collides with real decision-making. They know which unanswered questions continue to block confidence, which endpoints matter less in practice than the company assumes, and which patient populations remain outside the evidence even though they dominate clinical concern. The MSL sits close enough to that reality to help shape better evidence plans.

The first step is recognizing what kind of field feedback is relevant to evidence generation. Not every physician preference deserves a new study. What matters are repeated, clinically meaningful signals such as uncertainty around patient selection, lack of confidence in generalizing from trial populations, persistent concern about safety management in certain groups, questions about sequencing, unresolved biomarker interpretation, insufficient data in medically important populations, or practical barriers that real-world or implementation-focused evidence could help address. These are not just objections. They are potential design inputs.

MSLs should listen for evidence gaps in the language physicians actually use. A clinician may not say, “You need a pragmatic study in a less selected population.” The clinician may say, “These are not the patients I struggle with,” or “I still do not know how this behaves in the people I am actually worried about.” Another may not request a real-world evidence program directly, but may repeatedly describe how monitoring burden or referral delay changes what is possible in practice. The MSL’s job is to interpret these comments as clues to what evidence is missing or insufficiently translated.

Patterns matter here more than isolated anecdotes. A single physician’s irritation about a niche subgroup may be interesting but not strategic. Repeated concern across credible experts in different settings is much more important. Some of the strongest field contributions to evidence generation come from noticing that the same barrier appears in different languages across academic centers, community practices, integrated systems, and advisory settings. When that happens, the issue may deserve a place in medical affairs, evidence planning, future study concepts, observational work, publication efforts, or educational strategy.

It is useful to think about evidence-generation input in categories. Population gaps: which patients physicians feel are underrepresented or insufficiently understood. Endpoint gaps: where the study measured something valid but not fully persuasive to clinicians. Usage gaps: how sequencing, duration, monitoring, or combination use remain unclear. Implementation gaps: where diagnostic workflow, site capability, or health-system realities make current evidence hard to operationalize. Translation gaps: where the evidence may be adequate in principle but is not being interpreted clearly enough in practice. Not all of these require new trials, but all can influence evidence planning.

The MSL’s contribution becomes most valuable when the field signal is converted into a well-framed internal brief rather than a loose collection of quotes. A good evidence-generation input does four things. It defines the issue clearly: what is the unresolved question? It shows support: how broadly and credibly is the issue appearing? It explains why it matters: what decision or barrier does it affect? It suggests the type of response: additional study, subgroup analysis, real-world evidence, advisory exploration, publication focus, or improved medical education. That level of framing helps medical affairs and clinical teams use the signal rather than merely admire it.

A short field-to-evidence template can be highly effective:

• Unmet question: what are clinicians still unable to judge confidently?
• Who is raising it: which stakeholder types or institutions are surfacing the issue?
• Why it matters: how does the gap affect confidence, use, or patient care?
• Potential response: what evidence or analysis might address it?

For example, a strong synthesis might be: community and academic physicians remain uncertain about using the therapy in less-fit older patients because the pivotal population appears narrower than those commonly seen in practice; this uncertainty is slowing confidence in earlier-line use; consider whether ongoing evidence plans, real-world analyses, or future research concepts should address this population more directly. That is much more useful than “doctors want more data in older patients.”

The MSL should also know that not every evidence gap should lead straight to a study. Sometimes the right response is a better publication plan, a subgroup analysis that already exists but has not been explained well, a congress discussion guide, or an advisory board focused on interpreting the issue. Evidence generation should be broad enough to include new data creation and better data use. The medical field can inform both.

There is another strategic benefit here. Bringing field feedback into evidence planning helps prevent internal overconfidence. Companies often assume that because a data package is strong by traditional standards, the field will naturally know what to do with it. MSLs know that this is not always true. Physicians may accept the data and still remain unsure how to apply them. They may believe the endpoint and still doubt the population. They may like the efficacy but feel that the monitoring or biomarker burden changes the practical equation. These are not failures of intelligence in the field. They are reminders that evidence must land in real clinical systems. MSLs are among the few people positioned to explain that landing zone clearly.

The most valuable field feedback, then, is not “physicians have questions.” Of course they do. The value lies in identifying which questions persist, which matter most, and which evidence choices would most improve external confidence and patient care. That is where the MSL becomes a meaningful contributor to the company’s future evidence agenda rather than merely a reporter of current sentiment.

12.4 Partnering With Clinical and Medical Affairs Teams

No MSL supports clinical development and evidence generation alone. The role becomes effective only when it is connected to the teams that design studies, review external concepts, shape medical strategy, prioritize publications, and govern evidence investments. The quality of that partnership depends less on goodwill than on clarity. Each function should understand what the MSL sees, what the MSL does not own, and how field input is supposed to travel into action.

With medical affairs teams, the partnership is often closest. Medical directors and evidence leaders need to know what questions physicians are asking, which experts are signaling unmet need, and where current evidence appears strong, weak, misunderstood, or incomplete. The MSL, in turn, needs enough visibility into the medical plan to recognize what types of field input are most valuable. This should feel like a two-way exchange, not a one-way reporting burden. Medical affairs sets the broad evidence agenda; field medical pressure-tests it against practice reality.

With clinical teams, the collaboration is usually more selective but still important. Clinical development, clinical science, and study leadership may need field perspective on site capability, relevance of proposed populations, likely interest among investigators, and early reactions to evidence themes that could influence future studies. The MSL should bring that perspective in a disciplined way, without pretending to speak for the entire market based on a few accounts. Clinical teams benefit most when the MSL translates field learning into concrete patterns and implications rather than anecdotes.

Good partnership also depends on clear handoffs. If the MSL hears a credible investigator concept, there should be a known route into the internal review process. If repeated field feedback suggests a meaningful evidence gap, there should be a forum where that synthesis is discussed with medical affairs leadership. If an investigator or site needs operational study support, the transition to clinical operations should be smooth and explicit. Ambiguity here wastes time and encourages role drift.

Regular operating rhythms help. Strong organizations create periodic field-to-evidence reviews where MSLs can bring structured themes, not just individual comments. They create pre-congress and post-congress touchpoints so evidence implications are interpreted quickly. They align around advisory boards and external expert plans so field medical input helps shape the right discussions. They also review which feedback truly merits action and which should simply be monitored. Not every signal deserves immediate change.

The MSL should approach these partnerships as a scientific contributor, not as a general messenger. That means showing up with pattern recognition, source quality, clinical context, and practical recommendations. It also means respecting decision rights. The MSL can frame the issue and suggest what may be worth exploring. The clinical and medical leadership teams ultimately decide what enters the evidence plan, what gets funded, what is publishable, and what remains a lower priority.

A simple standard improves cross-functional work: bring signals, not just stories. Teams can act on patterns, implications, and well-framed questions. They struggle to act on raw field noise. The MSL who consistently brings signals becomes far more influential than the one who reports every conversation equally.

When this partnership works well, the company becomes smarter. Clinical development gains a better sense of what will matter when data reach practice. Medical affairs become more realistic about where evidence translation is easy and where it is not. The medical field sees that its best observations change thinking upstream. That is the real promise of the MSL role in evidence generation: not owning the studies, but helping the right studies, analyses, and scientific priorities emerge from the reality of patient care.